Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack. However, up to 25-50% of patients who have angioplasty may have ongoing damage to the heart muscle when the blockage is opened and blood flow is restored. Complications which may result from this ongoing damage include a larger area of damaged muscle in the heart, enlargement of the heart, an increased risk of death, and an increased risk of heart failure. Some of the ongoing damage may involve increased levels of the protein kinase C (PKC) enzyme. KAI-9803 is a selective inhibitor of delta PKC. In this study, delta PKC is used with angioplasty and other standard procedures to restore blood flow after a heart attack. This study is designed to evaluate safety of different amounts of KAI-9803 when used in treating heart attack patients undergoing angioplasty. We will also try to evaluate whether KAI-9803 can reduce the amount of heart muscle damage and the complications that may occur in these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

NCT00785954

Myocardial Infarction Cardiovascular Diseases Pathologic Processes

COMPLETED PHASE2

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

NCT03113773

Ischemic Heart Disease

COMPLETED PHASE1/PHASE2

Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

NCT01882179

ST-elevation Myocardial Infarction

COMPLETED PHASE3

IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction

NCT01007461

ST-Segment Elevation Myocardial Infraction

WITHDRAWN PHASE2

Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction

NCT01584453

Myocardial Infarction Reperfusion Injury Myocardial Ischemia +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KAI-9803 for Injection

0.05 mg

Intervention Type DRUG

KAI-9803 for Injection

0.5 mg

Intervention Type DRUG

KAI-9803 for Injection

1.25 mg

Intervention Type DRUG

KAI-9803 for Injection

5 mg

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptoms of cardiac ischemia at rest or with increasing frequency (angina or angina equivalent), with episodes lasting for at least 30 minutes within 6 hours of presentation
* Persistent ST-segment elevation of ≥ 0.2 mV in at least 2 contiguous precordial leads indicative of anterior Myocardial Infarction (MI) location (leads V1-V4)
* At least 18 years old
* Complete occlusion of the left anterior descending artery (Thrombolysis in Myocardial Infarction (TIMI) 0-1 flow) demonstrated on the initial angiogram
* Culprit lesion suitable for primary percutaneous coronary intervention (PCI)

Exclusion Criteria

* Any left bundle branch block (new or old), intraventricular conduction defect, or paced rhythm that would obscure the diagnosis of acute anterior ST Elevation Myocardial Infarction (STEMI)
* Any prior documented myocardial infarction (MI), including old Q waves documented on prior ECGs or a clinical history of definite MI
* Any prior coronary artery bypass grafting (CABG)
* Cardiogenic shock at initial hospital presentation, consisting of persistent hypotension (systolic blood pressure \< 90 mm Hg for \> 20 minutes) and signs of end-organ dysfunction (oliguria, altered mental status, poor peripheral perfusion, and lactic acidosis)
* TIMI grade 2 or 3 flow in the left anterior descending artery documented on the initial diagnostic angiogram
* Culprit lesion in the left anterior descending artery that is not suitable for primary PCI
* Treatment with intravenous fibrinolytic therapy (i.e. alteplase, reteplase, tenecteplase, or streptokinase) within the 24 hours before presentation
* Pregnancy
* Know baseline creatinine \> 2.5 mg/dL without renal dialysis/renal replacement therapy within the 30 days before presentation
* Inability to comply with study procedures, inability to undergo cardiac catheterization or primary percutaneous coronary intervention (PCI)
* Participation in a study of experimental therapy (drug or device) within 30 days of presentation, or prior participation in this study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No